Aquaculture biotechnology firm Benchmark is expected to exceed market expectations for its annual financial results, the company said.
In a market announcement this morning, Benchmark said it plans to report “stronger than expected business performance in its three business areas” for the year through September 30, 2021.
This includes the continued growth of the Animal Nutrition division, a strong year-end for Benchmark Genetics and, for the Healthcare division, the first revenues from the company’s new sea lice treatment, Ectosan® Vet and CleanTreat. ®.
Annual results will be announced on November 29.
The company said: “Although still audited, the Group’s Adjusted EBITDA for fiscal 21 is expected to be significantly higher than the current market consensus of £ 15.9 million.
Trond Williksen, CEO, commented: “We are delighted with the continued momentum of the business, which reflects the benefits of our clear business focus, streamlining of the organization, our continued and disciplined approach to cost control and good demand for our products in our markets.
“As an aquaculture biotechnology company specializing in three strong business areas, we are well positioned to seize market opportunities and generate profitable growth. “